JP2011509955A - 抗骨髄腫薬としてのイソチオシアネート誘導体の使用 - Google Patents
抗骨髄腫薬としてのイソチオシアネート誘導体の使用 Download PDFInfo
- Publication number
- JP2011509955A JP2011509955A JP2010542529A JP2010542529A JP2011509955A JP 2011509955 A JP2011509955 A JP 2011509955A JP 2010542529 A JP2010542529 A JP 2010542529A JP 2010542529 A JP2010542529 A JP 2010542529A JP 2011509955 A JP2011509955 A JP 2011509955A
- Authority
- JP
- Japan
- Prior art keywords
- gmg
- itc
- myeloma
- treatment
- glucomoringin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
本発明は、骨髄腫治療のための薬剤を調製するための、以下の式(I、II)を有するグルコモリンギンおよびそのデスチオグルコシドの使用に関する。
Description
植物は、化学的予防活性を有する最も重要な化合物源である。この中で、アブラナ科(Brassicaceae)(例えば、ブロッコリー、芽キャベツ、カリフラワーなど)において産生されるイソチオシアネート(ITC)は、ITCに誘発された腫瘍増殖阻害についてのSidranskyの最初の研究[1]以来、現在、多くの興味を引きつけている。
ここで、以下の式:
例1 化合物の単離および精製
GMGおよびGRAは、それぞれ、モリンガ・オレイフェラL.(Moringa oleifera L.)(カラシノキ科)およびブラッシカ・オレラケアL.(Brassica oleracea L.)(アブラナ科;変種acephara;亜種laciniata)種子からそれぞれ単離された。両GLは、以前に報告された方法[27、28]に従って、アニオン交換クロマトグラフィーおよびサイズ排除クロマトグラフィーによる、2つの連続ステップで精製した。個々のGLは、1H NMR分光法および13C NMR分光法によって特徴付け、精製物を、ISO 9167−1法[29]に従って、脱スルホ化誘導体のHPLC分析によって分析すると、ピーク面積値基準の収量が約99%であったが、これらは吸湿性が高いため、重量基準で約90〜92%であった。酵素MYRは、報告された方法[30]にいくつかの変更を加えて、シロガラシL.(Sinapis alba L.)の種子から単離した。本試験で使用した貯蔵液は、可溶性タンパク質の比活性度が約60単位/mgであり、H2O中で34U/mlに希釈した後、4℃で保存した。1MYR単位は、pH6.5および37℃において、シニグリンを1μモル/分で加水分解できる酵素量として規定した。MYR溶液は、使用するまで滅菌蒸留水中、4℃で保管した。GMG−ITCは、ミロシナーゼ触媒によるGMGの加水分解を介して生成させた(37℃において、pH6.5の0.1Mリン酸バッファー中で行った)。反応混合物は、7.0グラムの純GMGを350mLのバッファー中で溶解した後、40Uのミロシナーゼを加え、溶液を37℃で4〜6時間保存して調製した。純GMGのGMG−ITCへの完全な変換は、脱スルホ化誘導体のHPLC分析によって確認し[29]、これにより、我々は、反応混合物中におけるGMGの完全消失まで、還元を監視することができた。次に、アセトニトリルを、最終濃度が10%になるまで混合物に加え、GMG−ITCを逆相クロマトグラフィーによって精製した(この操作は、Frac−900フラクションコレクターおよびUVモニターUPC−900(Amersham Bioscences)を備え付けたAKTA−FPLCに接続した、LiChrospher RP−C18(MERCK)またはSOURCE15 RPC(Amersham Biosciences)を充填したHR16/10カラムを使用して行った)。アセトニトリル10%で洗浄後、溶出を、60%のアセトニトリルまで勾配をかけて行った。画分を収集し、Inertsil ODS3カラム(250x3mm、5mm)を有する、Hewlett−Packardモデル1100 HPLCシステムを用いて分析した。クロマトグラフィーは、30℃において、流速1mL/分で、水(A)およびアセトニトリル(B)の直線勾配を、20分間でBの30%から80%かける溶出により行った。GMG−ITCの溶出は、229nmにおける吸収を監視しながら、ダイオードアレイで検出した。GMG−ITC(ピーク純度>99%)を含有する画分を収集し、溶媒をロータリーエバポレーター内での濃縮により除去し、最終溶液を凍結乾燥した。GMG−ITCを、1H NMRおよび13C NMR、ならびに質量分析法により特徴付け、明白に同定した。
例2 生物学的結果
試験管内データ:
表1は、グルコモリンギンに対するH460ヒト肺腫瘍細胞株の感受性を示す。ミロシナーゼ存在下のGMGの濃度増大は、細胞毒性作用をもたらす。
生体内試験
表3では、皮下注射で移植したヒト骨髄腫の腫瘍細胞株を有するSCIDマウスに生体内投与したGMG−ITCの抗腫瘍活性を報告する。
Claims (4)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08100658.7 | 2008-01-18 | ||
EP08100658A EP2080516B1 (en) | 2008-01-18 | 2008-01-18 | Use of isothiocyanate derivatives as anti-myeloma agents |
PCT/EP2008/010768 WO2009089889A1 (en) | 2008-01-18 | 2008-12-17 | Use of isothiocyanate derivatives as anti-myeloma agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011509955A true JP2011509955A (ja) | 2011-03-31 |
JP5386507B2 JP5386507B2 (ja) | 2014-01-15 |
Family
ID=39247811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010542529A Expired - Fee Related JP5386507B2 (ja) | 2008-01-18 | 2008-12-17 | 抗骨髄腫薬としてのイソチオシアネート誘導体の使用 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8772251B2 (ja) |
EP (1) | EP2080516B1 (ja) |
JP (1) | JP5386507B2 (ja) |
KR (1) | KR101523042B1 (ja) |
CN (1) | CN101918006B (ja) |
AT (1) | ATE511845T1 (ja) |
AU (1) | AU2008347390B2 (ja) |
CA (1) | CA2712258C (ja) |
DK (1) | DK2080516T3 (ja) |
ES (1) | ES2363385T3 (ja) |
HR (1) | HRP20110451T1 (ja) |
IL (1) | IL207011A (ja) |
PL (1) | PL2080516T3 (ja) |
PT (1) | PT2080516E (ja) |
RU (1) | RU2480217C2 (ja) |
SI (1) | SI2080516T1 (ja) |
WO (1) | WO2009089889A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10647668B2 (en) | 2011-01-03 | 2020-05-12 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US11279674B2 (en) | 2011-01-03 | 2022-03-22 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactant and associated method of use |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US8933119B2 (en) | 2011-01-03 | 2015-01-13 | The William M. Yarbrough Foundation | Method for treating phytophotodermatitis |
US10640464B2 (en) | 2011-01-03 | 2020-05-05 | The William M. Yarbrough Foundation | Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
US10273205B2 (en) | 2011-01-03 | 2019-04-30 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms |
US10308599B2 (en) | 2011-01-03 | 2019-06-04 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US11407713B2 (en) | 2011-01-03 | 2022-08-09 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US8865765B2 (en) | 2011-01-12 | 2014-10-21 | The William M. Yarbrough Foundation | Method for treating eczema |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
RU2014116229A (ru) | 2011-09-23 | 2015-10-27 | Даблхил Гмбх | Новые соединения изоцианата и изотиоцианата для лечения злокачественных новообразований |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
US10080734B2 (en) | 2012-07-26 | 2018-09-25 | The William M. Yarbrough Foundation | Method for treating autism and other neurodevelopmental disorders |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
WO2014018874A1 (en) | 2012-07-26 | 2014-01-30 | The William M. Yarbrough Foundation | Method for treating skin cancer |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
US9949943B2 (en) | 2012-07-26 | 2018-04-24 | The William M. Yarbrough Foundation | Method for treating neurodegenerative diseases |
US9839621B2 (en) | 2012-07-26 | 2017-12-12 | The William M. Yarbrough Foundation | Method for treating bladder cancer |
CN103262850B (zh) * | 2013-01-16 | 2014-06-11 | 长沙理工大学 | 一种石蒜生长促进剂及其使用方法 |
EA026332B1 (ru) * | 2013-03-14 | 2017-03-31 | Общество с ограниченной ответственностью "Тиацен" | Применение производных роданина для профилактики и/или лечения опухолевых заболеваний |
US20160243176A1 (en) * | 2013-11-01 | 2016-08-25 | Rutgers, The State University Of New Jersey | Extracts from plants of the moringaceae family and methods of making |
EP3078371A1 (en) | 2015-04-10 | 2016-10-12 | INDENA S.p.A. | Use of isothiocyanate derivatives as modulators of peripheral and neuropathic pain |
CN107857781A (zh) * | 2017-11-16 | 2018-03-30 | 云南农业大学 | 一种从辣木籽中制备4‑α‑L‑鼠李糖基‑异硫氰酸苄酯的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004519423A (ja) * | 2000-08-21 | 2004-07-02 | ジェド ダブリュ. ファーヒー | イソチオシアネートを用いたヘリコバクターの治療方法 |
WO2006065736A2 (en) * | 2004-12-14 | 2006-06-22 | Johns Hopkins University | Method of extraction of isothiocyanates into oil from glucosinolsate-containing plants |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6988664B1 (en) * | 2004-09-30 | 2006-01-24 | Symbol Technologies, Inc. | Removable cover for an electronic device |
-
2008
- 2008-01-18 PL PL08100658T patent/PL2080516T3/pl unknown
- 2008-01-18 SI SI200830332T patent/SI2080516T1/sl unknown
- 2008-01-18 PT PT08100658T patent/PT2080516E/pt unknown
- 2008-01-18 ES ES08100658T patent/ES2363385T3/es active Active
- 2008-01-18 DK DK08100658.7T patent/DK2080516T3/da active
- 2008-01-18 AT AT08100658T patent/ATE511845T1/de active
- 2008-01-18 EP EP08100658A patent/EP2080516B1/en active Active
- 2008-12-17 RU RU2010129238/15A patent/RU2480217C2/ru active
- 2008-12-17 US US12/812,970 patent/US8772251B2/en not_active Expired - Fee Related
- 2008-12-17 KR KR1020107015671A patent/KR101523042B1/ko active IP Right Grant
- 2008-12-17 JP JP2010542529A patent/JP5386507B2/ja not_active Expired - Fee Related
- 2008-12-17 CN CN2008801248596A patent/CN101918006B/zh not_active Expired - Fee Related
- 2008-12-17 AU AU2008347390A patent/AU2008347390B2/en not_active Ceased
- 2008-12-17 WO PCT/EP2008/010768 patent/WO2009089889A1/en active Application Filing
- 2008-12-17 CA CA2712258A patent/CA2712258C/en not_active Expired - Fee Related
-
2010
- 2010-07-15 IL IL207011A patent/IL207011A/en active IP Right Grant
-
2011
- 2011-06-16 HR HR20110451T patent/HRP20110451T1/hr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004519423A (ja) * | 2000-08-21 | 2004-07-02 | ジェド ダブリュ. ファーヒー | イソチオシアネートを用いたヘリコバクターの治療方法 |
WO2006065736A2 (en) * | 2004-12-14 | 2006-06-22 | Johns Hopkins University | Method of extraction of isothiocyanates into oil from glucosinolsate-containing plants |
Non-Patent Citations (2)
Title |
---|
JPN6013003233; Mutation Research 440, 1999, 181-188 * |
JPN6013003236; Trees for Life Journal 1(5), 20051201 * |
Also Published As
Publication number | Publication date |
---|---|
RU2480217C2 (ru) | 2013-04-27 |
KR101523042B1 (ko) | 2015-05-26 |
KR20100102660A (ko) | 2010-09-24 |
ES2363385T3 (es) | 2011-08-02 |
PT2080516E (pt) | 2011-07-01 |
HRP20110451T1 (hr) | 2011-07-31 |
IL207011A0 (en) | 2010-12-30 |
CN101918006B (zh) | 2012-11-21 |
DK2080516T3 (da) | 2011-07-11 |
RU2010129238A (ru) | 2012-01-20 |
AU2008347390A1 (en) | 2009-07-23 |
CA2712258A1 (en) | 2009-07-23 |
CA2712258C (en) | 2013-12-10 |
WO2009089889A1 (en) | 2009-07-23 |
AU2008347390B2 (en) | 2014-03-13 |
EP2080516B1 (en) | 2011-06-08 |
CN101918006A (zh) | 2010-12-15 |
EP2080516A1 (en) | 2009-07-22 |
PL2080516T3 (pl) | 2011-12-30 |
IL207011A (en) | 2014-04-30 |
US20110053870A1 (en) | 2011-03-03 |
JP5386507B2 (ja) | 2014-01-15 |
SI2080516T1 (sl) | 2011-09-30 |
ATE511845T1 (de) | 2011-06-15 |
US8772251B2 (en) | 2014-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5386507B2 (ja) | 抗骨髄腫薬としてのイソチオシアネート誘導体の使用 | |
Shu et al. | Antitumor immunostimulatory activity of polysaccharides from Panax japonicus CA Mey: Roles of their effects on CD4+ T cells and tumor associated macrophages | |
Brunelli et al. | The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo | |
Alarifi et al. | Blood chemical changes and renal histological alterations induced by gentamicin in rats | |
Venditti et al. | Sulfur-containing secondary metabolites as neuroprotective agents | |
KR20150021465A (ko) | 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
CA2749931C (en) | Use of pterosin compounds for treating diabetes and obesity | |
EP3308781A1 (en) | Blood pressure-lowering agent | |
US20150087606A1 (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
NO343552B1 (no) | Sammensetninger for behandling av kroniske degenerative inflammatoriske tilstander | |
Abdelkader et al. | Ameliorative Effect of Eruca sativa seeds and its rutin on gentamicin‑induced nephrotoxicity in male rats via targeting inflammatory status, oxidative stress and kidney injury molecule-1 (KIM-1)/cystatin c expression | |
CA3090394A1 (en) | Methods for treating mitochondrial disorders | |
WO2014030763A1 (ja) | 抗腫瘍剤 | |
US11717502B2 (en) | Blood flow improver | |
WO2022220265A1 (ja) | サーチュイン又はクロトー活性化又は発現増強剤、nad+増加剤、及び老化細胞抑制剤 | |
US20060240120A1 (en) | Composition for lowering blood glucose | |
WO1991009603A1 (en) | Ganglioside derivatives and their use as medicaments | |
Wu et al. | Extraction, structural properties, and bioactivities of Moringa (Moringa oleifera Lam.) isothiocyanates: A review | |
KR20190142672A (ko) | 강황 추출물을 포함하는 간손상 예방 및 치료용 약학 조성물 | |
JP2022168636A (ja) | ヤヌスキナーゼ阻害剤 | |
KR102090089B1 (ko) | 히스피돌을 유효성분으로 포함하는 우울증 또는 불안증의 예방 또는 치료용 조성물 | |
JP6588764B2 (ja) | 抗腫瘍剤 | |
JP2023141229A (ja) | 高リン血症治療用医薬用組成物 | |
WO2022232109A1 (en) | Synthesis of cbn and cbnv | |
WO2014069255A1 (ja) | 抗がん剤、及び併用抗がん剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130430 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130910 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131007 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5386507 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |